Treatment of Hypothalamic Obesity with Caffeine and Ephedrine
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several central stimulants have been used off label for the treatment of hypothalamic obesity such as methylphenidate, phentermine, dextroamphetamine, mazindol, caffeine, and ephedrine (121, 122, 137-139), but data on these drugs are based on small studies with mixed results.”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [137]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Research works printed but not linked: 30
- Meuric, 2005, Influence of tumor location on the presentation and evolution of craniopharyngiomas, J Neurosurg., 103, 421
- Frohlich, 1901, Ein Fall von Tumor der Hypophysis cerebri ohne Akromegalie, Weiner Klin Rdsch., 15, 883
- Bruch, 1939, The Frohlich syndrome: report of the original case, Am J Dis Child., 58, 1281, 10.1001/archpedi.1939.01990110146014 · doi:10.1001/archpedi.1939.01990110146014
- Babinski, 1900, Tumeur du corps pituitaire sans acromegalie et avec arret de developpement des organes genitaux, Rev Neurol., 8, 531
- Erdheim, 1904, Uber Hypophysenganggeschwulste und Hirncholesteatome, Sitzungsb Akad Wissenchafften (Wein)., 113, 537
- Bray, 1975, Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature, Medicine (Baltimore)., 54, 301, 10.1097/00005792-197507000-00002 · DOI · Paper page
- Reeves, 1969, Hyperphagia, rage, and dementia accompanying a ventromedial hypothalamic neoplasm, Arch Neurol., 20, 616, 10.1001/archneur.1969.00480120062005 · DOI · Paper page
- Brauner, 2006, Diencephalic syndrome due to hypothalamic tumor: a model of the relationship between weight and puberty onset, J Clin Endocrinol Metab., 91, 2467, 10.1210/jc.2006-0322 · DOI · Paper page
- Bray, 1992, Genetic, hypothalamic and endocrine features of clinical and experimental obesity [with discussion], Prog Brain Res., 93, 333, 10.1016/S0079-6123(08)64583-5 · DOI
- Perkins, 1981, Activation of brown adipose tissue thermogenesis by the ventromedial hypothalamus, Nature., 289, 401, 10.1038/289401a0 · DOI · Paper page
- King, 2006, The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight, Physiol Behav., 87, 221, 10.1016/j.physbeh.2005.10.007 · DOI · Paper page
- King, 1982, The role of vagally-mediated hyperinsulinemia in hypothalamic obesity, Neurosci Biobehav Rev., 6, 205, 10.1016/0149-7634(82)90056-2 · DOI
- Inoue, 1977, The effects of subdiaphragmatic vagotomy in rats with ventromedial hypothalamic obesity, Endocrinology., 100, 108, 10.1210/endo-100-1-108 · DOI · Paper page
- Berthoud, 1983, Evidence for a role of the gastric, coeliac and hepatic branches in vagally stimulated insulin secretion in the rat, J Auton Nerv Syst., 7, 97, 10.1016/0165-1838(83)90039-5 · DOI
- Tokunaga, 1986, Effect of vagotomy on serum insulin in rats with paraventricular or ventromedial hypothalamic lesions, Endocrinology., 119, 1708, 10.1210/endo-119-4-1708 · DOI · Paper page
- Sakaguchi, 1988, Sympathetic activity following paraventricular or ventromedial hypothalamic lesions in rats, Brain Res Bull., 20, 461, 10.1016/0361-9230(88)90135-9 · DOI
- Niijima, 1984, Role of ventromedial hypothalamus on sympathetic efferents of brown adipose tissue, Am J Physiol., 247, R650
- Vander Tuig, 1982, Reduced sympathetic nervous system activity in rats with ventromedial hypothalamic lesions, Life Sci., 30, 913, 10.1016/0024-3205(82)90619-1 · DOI
- Yoshida, 1984, Catecholamine turnover in rats with ventromedial hypothalamic lesions, Am J Physiol., 246, R558
- Jeanrenaud, 1983, Energy fuel and hormonal profile in experimental obesities, Experientia Suppl., 44, 57, 10.1007/978-3-0348-6540-1_5 · DOI
- York, 1972, Dependence of hypothalamic obesity on insulin, the pituitary and the adrenal gland, Endocrinology., 90, 885, 10.1210/endo-90-4-885 · DOI · Paper page
- Lustig, 1999, Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist, J Pediatr., 135, 162, 10.1016/S0022-3476(99)70017-X · DOI · Paper page
- Boosalis, 1992, Cholecystokinin and satiety: effect of hypothalamic obesity and gastric bubble insertion, Am J Physiol., 262, R241
- Greenway, 2001, The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent, Obes Rev., 2, 199, 10.1046/j.1467-789x.2001.00038.x · DOI · Paper page
- Astrup, 1992, The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial, Int J Obes Relat Metab Disord., 16, 269
- 1990, World Health Organization Diet, nutrition and the prevention of chronic diseases: report of a WHO study group, WHO Tech Rep Ser., 797
- Astrup, 1992, The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women, Metabolism., 41, 686, 10.1016/0026-0495(92)90304-S · DOI
- Dulloo, 1993, Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis, Int J Obes Relat Metab Disord., 17, S35
- Lustig, 2003, Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial, J Clin Endocrinol Metab., 88, 2586, 10.1210/jc.2002-030003 · DOI · Paper page
- Lustig, 2006, A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion, Int J Obes (Lond)., 30, 331, 10.1038/sj.ijo.0803074 · DOI
Cited by
van Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
Müller, H. L., Tauber, M., Lawson, E. A., Özyurt, J., Bison, B., Martinez-Barbera, J.-P., Puget, S., Merchant, T. E., & van Santen, H. M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00351-z · Cited by 144
Hamilton, J., Conwell, L., Syme, C., Ahmet, A., Jeffery, A., & Daneman, D. (2011) · International Journal of Pediatric Endocrinology · doi:10.1155/2011/417949 · Cited by 109
“A recent pilot study of caffeine and ephedrine given to 3 patients with hypothalamic obesity resulted in amean weight loss of 14% with 2 of the 3 patients sustaining weight loss for at least 2 years [27].”
BackgroundRoth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87
Roth, C. L., Scimia, C., Shoemaker, A. H., Gottschalk, M., Miller, J., Yuan, G., Malhotra, S., & Abuzzahab, M. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00087-1 · Cited by 76
Metadata
- Authors
- Greenway, F. L., & Bray, G. A.
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 14
- Issue
- 6
- Pages
- 697-703
- ISSN
- 1530-891X
- Cited by
- 50
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Hypothalamic Obesity with Caffeine and Ephedrine. https://app.cochat.ai/papers/10.4158/ep.14.6.697
- The paper
- Greenway, F. L., & Bray, G. A. (2008). Treatment of Hypothalamic Obesity with Caffeine and Ephedrine. Endocrine Practice. https://doi.org/10.4158/ep.14.6.697
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.